Open-label phase I clinical trial of Ad5-EBOV in Africans in China

Wu, Lihua; Zhang, Zhe; Gao, Hainv; Li, Yuhua; Hou, Lihua; Yao, Hang‐Ping; Wu, Shipo; Liu, Jian; Wang, Ling; Zhai, You; Ou, Huilin; Lin, Meihua; Wu, Xiaoxin; Liu, Jingjing; Lang, Guanjing; Xin, Qian; Wu, Guolan; Luo, Li; Liu, Pei; Shentu, Jianzhong; Wu, Nanping; Sheng, Jifang; Qiu, Yunqing; Chen, Wei; Li, Lanjuan

doi:10.1080/21645515.2017.1342021

Cited by 31 publications

(23 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Members of this species cause a significant proportion of acute respiratory tract infections in children [179,180]. Despite widespread pre-existing immunity, HAdV-C5 vectors are currently being used as vaccine platforms in many countries, principally against HIV [181,182], malaria [183,184,185], Ebola virus [186,187,188,189,190], influenza virus [191], tuberculosis [192,193], or in pre-clinical studies that are targeting Zika virus [194,195], Clostridium botulinum [196], type O foot-and-mouth disease virus [197], Middle East respiratory syndrome coronavirus [198,199], rabies virus [200,201], or Dengue virus [202]. In mice and NHPs, HAdV-C2 delivered antigens protected against Ebola virus [203].…”

Section: S and 1960s: Hadvs Etiology And Pathogenicitymentioning

confidence: 99%

A review of 65 years of human adenovirus seroprevalence

Mennechet

Paris

Ouoba

et al. 2019

Expert Review of Vaccines

132

135

View full text Add to dashboard Cite

Introduction: Human adenovirus (HAdV)-derived vectors have been used in numerous pre-clinical and clinical trials during the last 40 years. Current research in HAdV-based vaccines focuses on improving transgene immunogenicity and safety. Because pre-existing humoral immunity against HAdV types correlate with reduced vaccine efficacy and safety, many groups are exploring the development of HAdV types vectors with lower seroprevalence. However, global seroepidemiological data are incomplete. Areas covered: The goal of this review is to centralize 65 years of research on (primarily) HAdV epidemiology. After briefly addressing adenovirus biology, we chronical HAdV seroprevalence studies and highlight major milestones. Finally, we analyze data from about 50 studies with respect to HAdVs types that are currently used in the clinic, or are in the developmental pipeline. Expert opinion: Vaccination is among the most efficient tools to prevent infectious disease. HAdVbased vaccines have undeniable potential, but optimization is needed and antivector immunity remains a challenge if the same vectors are to be administrated to different populations. Here, we identify gaps in our knowledge and the need for updated worldwide epidemiological data.

show abstract

Section: S and 1960s: Hadvs Etiology And Pathogenicitymentioning

confidence: 99%

A review of 65 years of human adenovirus seroprevalence

Mennechet

Paris

Ouoba

et al. 2019

Expert Review of Vaccines

132

135

View full text Add to dashboard Cite

show abstract

“…However, it was found that pre-existing anti-HAd5 antibodies which are present in a large proportion of the human population could significantly dampen the humoral and cellular immune response to the vaccine antigen. 25 Various strategies have since been explored to circumvent this problem: the use of alternative human serotypes, such as HAd26 or HAd35, 26 re-engineering the capsid of HAd5 to prevent antibody recognition, 27 and the use of simian adenoviral vectors against which there is no pre-existing immunity. 28 As discussed above, chimpanzee adenoviral vectors (ChAds) have successfully been used in clinical trials against a variety of diseases.…”

Section: Progression Of the Vectored Vaccine Approach: Success Of Rapmentioning

confidence: 99%

Chimpanzee adenoviral vectors as vaccines for outbreak pathogens

Ewer

Sebastian

Spencer

et al. 2017

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

The 2014–15 Ebola outbreak in West Africa highlighted the potential for large disease outbreaks caused by emerging pathogens and has generated considerable focus on preparedness for future epidemics. Here we discuss drivers, strategies and practical considerations for developing vaccines against outbreak pathogens. Chimpanzee adenoviral (ChAd) vectors have been developed as vaccine candidates for multiple infectious diseases and prostate cancer. ChAd vectors are safe and induce antigen-specific cellular and humoral immunity in all age groups, as well as circumventing the problem of pre-existing immunity encountered with human Ad vectors. For these reasons, such viral vectors provide an attractive platform for stockpiling vaccines for emergency deployment in response to a threatened outbreak of an emerging pathogen. Work is already underway to develop vaccines against a number of other outbreak pathogens and we will also review progress on these approaches here, particularly for Lassa fever, Nipah and MERS.

show abstract

“…128,129 Nonreplicating Viral Vectorebased Vaccines Human Ad5 was used for some early viral vector vaccines, but the cellular and humoral immune responses to vaccine inserts were inhibited by preexisting neutralizing antibodies to the vector. 130 To overcome this challenge, researchers shifted to vectors based on other serotypes with lower seroprevalence, such as Ad26 and Ad35, 131 chimeric forms of adenovirus to prevent immune recognition (Ad5H3) using the antigen capsid-incorporation technique, 132 and the chimpanzee-adenovirus vector to which most humans have not been previously exposed. 133 In the antigen capsideincorporation strategy, chimeric Ad5H3 was created by adding a polyhistidine sequence (His 6 ) into the hexon3 (H3) capsid protein of Ad5.…”

Section: Dna-based Vaccinesmentioning

confidence: 99%

Innovations in HIV-1 Vaccine Design

Jones

Moody

Thompson

2020

Clinical Therapeutics

View full text Add to dashboard Cite

Purpose: The field of HIV-1 vaccinology has evolved during the last 30 years from the first viral vector HIV gene insert constructs to vaccination regimens using a myriad of strategies. These strategies now include germline-targeting, lineagebased, and structure-guided immunogen design. This narrative review outlines the historical context of HIV vaccinology and subsequently highlights the scientific discoveries during the last 6 years that promise to propel the field forward.Methods: We conducted a search of 2 electronic databases, PubMed and EMBASE, for experimental studies that involved new HIV immunogen designs between 2013 and 2019. During the title and abstract reviews, publications were excluded if they were written in language other than English and/or were a letter to the editor, a commentary, or a conference-only presentation. We then used ClinicalTrials.gov to identify completed and ongoing clinical trials using these strategies.Findings: The HIV vaccinology field has undergone periods of significant growth during the last 3 decades. Findings elucidated in preclinical studies have revealed the importance of the interaction between the cellular and humoral immune system. As a result, several new rationally designed vaccine strategies have been developed and explored in the last 6 years, including native-like envelope trimers, nanoparticle, and mRNA vaccine design strategies among others. Several of these strategies have shown enough promise in animal models to progress toward first-inhuman Phase I clinical trials.Implications: Rapid developments in preclinical and early-phase clinical studies suggest that a tolerable and effective HIV vaccine may be on the horizon. (Clin Ther. xxxx;xxx:xxx)

show abstract

Open-label phase I clinical trial of Ad5-EBOV in Africans in China

Abstract: The application of Ad5-EBOV demonstrated safe in Africans in China and a specific GP antibody and T-cell response could occur 14 d after the first immunization. This acceptable safety profile provides a reliable basis to proceed with trials in Africa.

Cited by 31 publications

References 15 publications

A review of 65 years of human adenovirus seroprevalence

A review of 65 years of human adenovirus seroprevalence

Chimpanzee adenoviral vectors as vaccines for outbreak pathogens

Innovations in HIV-1 Vaccine Design

Contact Info

Product

Resources

About